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Abstract
Purpose To accurately estimate the effect size of both local or classic ischaemic preconditioning (IPC) and remote ischaemic
preconditioning (RIPC) using a pooling data set of 91 animals.
Methods We combined all the available mouse data collected from our Institute over the last 3 years regarding (i) local IPC
(4 cycles of 5 min of global ischaemia/reperfusion injury, IRI, followed by 35-min ischaemia and 2-h reperfusion) in the
Langendorff-isolated perfused mouse heart model and (ii) RIPC (3 cycles of 5 min of limb occlusion followed by 40-min
ischaemia and 2-h reperfusion) in the in vivo mouse model.
Results Five independent experiments containing 27 control and 29 IPC mice were used to estimate the overall (i) local IPC
effect, which reduced infarct size in the ex-vivo setting by a mean difference of 24.1% (95% CI 19.5, 28.6%) when compared to
untreated controls (P < 0.001) and for (ii) RIPC, three independent experiments including data for 16 control and 19 RIPC mice
were used to estimate that RIPC diminished infarct size in the in-vivo setting by a mean difference of 20.8% (95% CI 14.7,
26.9%) when compared to controls (P < 0.001).
Conclusions Using a significant animal dataset, we found that local IPC reduces myocardial infarct size by 24.1% and RIPC by
20.8% in the ex vivo and in vivo mouse models of IRI, respectively. These differences may be used as reference values to either
establish positive controls or to determine by how much myocardial infarct size can be reduced by novel cardioprotective
interventions following an IRI insult.
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Introduction
In many countries, basic animal research receives more
funding than clinical research on the assumption that it would
benefit humans in the long-run [1]. Animal experiments are
pivotal to decide what treatment should be taken forward in
clinical trials, but the reported treatment effect need to be valid
and precise. Biased or imprecise results from animal experi-
ments may result in exposing patients to unnecessary risks and
wasting scarce research funds. There is a need to report accu-
rate estimates of treatment effects, not only as the previous
step to translate treatments to the clinical setting, but also to
be used as a landmark for future animal studies. Repeatable,
reliable, and valid treatment effect estimates are the starting
point for many researchers who want to investigate any
intervention.
Targeting myocardial injury that paradoxically occurs with
the acute reperfusion of ischaemic myocardium remains one
of the top ten unmet clinical needs in cardiology [2]. Although
myocardial reperfusion is needed to salvage viable myocardi-
um in patients presenting with acute myocardial infarction
(AMI), it comes at a price in what is known as reperfusion-
induced injury (IRI). Therapies aimed to protect the heart
against IRI, known as cardioprotective therapies [3], include
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local ischaemic preconditioning (IPC), whereby brief cycles
of coronary occlusion and reperfusion elicit protection from a
prolonged IRI. This procedure has emerged as the paradigm of
cardioprotection [3] in the animal setting being highly repro-
ducible between laboratories and across species [4]. Both lo-
cal IPC and remote ischaemic preconditioning (RIPC) have
become pivotal in the assessment of novel cardioprotective
interventions. First, they are used as positive controls when
testing for other cardioprotective therapies. Second, they have
been used to unveil the molecular architecture behind the pro-
tection against IRI, as it is believed that most cardioprotective
interventions share common signalling pathways.
Whilst it is well known that both IPC and RIPC protect the
heart against IRI, many unanswered questions remain open to
debate. For instance, no consensus has been reached on how
many cycles should be applied for optimal protection and
what their duration and timing should be [5], or to which
extent the interval between preconditioning stimulus and the
index ischaemia affects the outcome. There is also little evi-
dence on whether local IPC or RIPC provide similar treatment
size, and most of this evidence comes from meta-analyses
using aggregated data in exceedingly heterogeneous experi-
mental conditions [4, 6]. In this small study, we combined all
the available animal data collected over the last 3 years regard-
ing the use of IPC in the Langendorff perfused isolated mouse
heart model and RIPC in the in vivo mouse model from our
Institution. The aim is to use this pool of more than 90 animals
to provide accurate estimate of the effect size of both IPC and
RIPC.
Methods
All work was conducted in accordance with the Guidelines on
the Operation of the Animals (Scientific Procedures) Act
1986, published by The Stationery Office (London, UK),
conforming with National Institute of Health Guidelines for
the Care and Use of Laboratory Animals.
Data Acquisition
We constructed a common data set by merging the individual
experimental data captured over a period of 3 years by two
independent researchers, one focused on IPC in the ex vivo
mouse model and the other one focused onRIPC in the in vivo
mouse model. Using data from five separate sets of IPC
ex vivo experiments, 56 animals were randomized to either
IPC (4 cycles of 5 min of global IRI followed by 35-min
ischaemia and 2-h reperfusion, n = 29 animals) or control
(40 min of buffer perfusion followed by 35-min ischaemia
and 2-h reperfusion, n = 27 animals). Using data from three
separate sets of RIPC in vivo experiments, 35 animals were
randomized to either RIPC (3 cycles of 5 min of limb
occlusion followed by 40-min ischaemia and 2-h reperfusion,
n = 19 animals) or control (sham procedure followed by 40-
min ischaemia and 2-h reperfusion, n = 16 animals) (Fig. 1).
To avoid publication bias, we used all animal data available,
regardless of whether these were used in previous peer review
publications or as part of ongoing studies [7–9].
Ex Vivo Isolated Langendorff-Perfused Mouse Heart
Model of Acute Myocardial Infarction
Heart isolation and Langendorff perfusion were carried out
with filtered modified Krebs-Henseleit buffer (composed of
118 mmol/L NaCl, 25 mmol/L NaHCO3, 11 mmol/L glucose,
4.7 mmol/L KCl, 1.22 mmol/L MgSO4.7H20, 1.21 mmol/L
KH2PO4, and 1.84 mmol/L CaCl2.2H20) aerated with a mix-
ture of O2 (95%) and CO2 (5%) to maintain pH at 7.40 ± 0.3,
as previously described [10]. Previously, mice were given
terminal anesthesia through an intraperitoneal injection of
60 mg/kg sodium pentobarbitone and anticoagulation
(100 IU heparin). Hearts were then harvested and immediately
cannulated through a 21-gauge cannula whilst submerged in
ice-cold modified Krebs-Henseleit buffer to be eventually per-
fused on a murine Langendorff perfusion apparatus at
80 mmHg pressure. There were three predefined exclusion
criteria: (1) 4 min exceed between heart removal and the
Langendorff-perfusion starting time, (2) temperature outside
the range of 37 ± 0.5 °C, and (3) isolated heart flow rate of
either less than 1 mL/min or more than 6.5 mL/min on the
Langendorff preparation during the 20-min stabilization peri-
od. After evaluating for exclusion criteria this stabilization
period, hearts were either allocated to IPC treatment or control
and subsequently subjected to 35 min of ischaemia and
120 min of reperfusion.
In Vivo Murine Model of Acute Myocardial Infarction
C57Bl/6 mice were anaesthetized by intraperitoneal injection
of 80 mg/kg pentobarbitone at a concentration of 20 mg/ml in
0.9% (w/v) saline and maintained at 36.5 ± 0.5 °C on a heating
mat. Surgery was started after confirming the abolishment of
pedal and tail reflexes and depth of anaesthesia was monitored
throughout. Mice were intubated using a 19G cannula and
ventilated with room air using a MiniVent, type 845, Small
Animal Ventilator (Harvard Apparatus, Kent, UK), at a flow
rate of 1.0 l/min with 2 cmH2O PEEP, stroke volume 200 μl at
130 strokes/min. The left anterior descending (LAD) coronary
artery was occluded in all mice (verified by ST elevation,
hypokinesia and pallor) for 40 min followed by 2 h
reperfusion.
RIPC was induced using a 6-mm lumen custom vascular
occluder (Kent Scientific, Torrington, CT, USA) around the
right hindlimb inflated to 250 mmHg to induce 3 cycles of 5-
min ischaemia, followed by 5-min reperfusion after each
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cycle. Blood flow was visualized in the hindlimb during RIPC
using a FLPI-2 laser speckle contrast blood flow imager
(Moor Instruments, Axminster, United Kingdom), which de-
livers images at high time and spatial resolution. Hair was first
removed from both hindlimbs using Veet depilation. Full-
frame images were recorded at 5 Hz and then subsequently
analysed by averaging the image intensity over an area of
interest encompassing the entire exposed upper limb. Limb
muscle pO2 was measured regularly using a bare-fibre phos-
phorescent sensor connected to an Oxylite™monitor (Oxford
Optronix, Abingdon, United Kingdom). The probe was pre-
coated with a 10 U/ml solution of heparin in saline to prevent
hematoma, then slowly inserted into the vastus intermedius
muscle along the track of a puncture made using a 21G × 5/
8″Microlance needle to a depth of 5 mm. tPO2 measurements
were continuously recorded using PowerLab 4/25 coupled to
Chart 7 (AD Instruments, Oxon, UK).
At the conclusion of the protocol, animals were euthanized
by severing of the aorta and subsequent exsanguination.
Myocardial infarct size (IS) was subsequently measured as
explained below.
Determination of Infarct Size
At the conclusion of the protocol, the heart was either
removed from the Langendorff apparatus (ex vivo ex-
periments) or else isolated from the animal and the aor-
tic root cannulated (in vivo experiments), and 5 mL of
1% 2,3,5-triphenyltetrazolium chloride (TTC) in
phosphate-buffered saline injected through the aortic
cannula and incubated for 10 min at 37 °C in order to
demarcate the infarcted (white) versus viable (red) tissue
[11]. For in vivo experiments, the LAD coronary artery
was re-ligated in order to perfuse Evans blue dye (2 mL
of 0.5%) to delineate the area at risk (AAR). After the
incubation, hearts were frozen overnight at − 20 °C and
sectioned perpendicular to the long axis the day after,
being the slices transferred into 10% neutral formalin
buffer for 1 h at room temperature. Images were taken
and evaluated through planimetry analysis using Image
J version 1.47 (NIH, Bethesda, MD) to quantify myo-
cardial IS as a percentage of the AAR.
Statistical Analysis
All data were pooled in the same unit of analysis (per-
centage of IS over AAR) and shown as mean (SEM).
For each independent experiment, we calculated the ef-
fect size as a raw difference in means (the means of the
experimental group, either IPC or RIC, minus the mean
of the control group) of the percentage of myocardial IS
and corresponding 95% CI and used linear regression
models to establish comparisons between groups (IPC
vs. control for five independent experiments and RIPC
vs. control for three independent experiments). To esti-
mate the overall effect of each intervention with higher
accuracy, we used random effect models, in which some
heterogeneity is allowed, and take into account the pre-
cision of individual experiments and the variation be-
tween experiments (between-experiment variation),
weighting each experiment accordingly to obtain an
overall estimate.
The robustness of our findings was tested in a sensitivity
analysis by performing an additional analysis using the
Fig. 1 Study protocols to assess
the impact on infarct size of
ischaemic preconditioning either
applied locally in the ex vivo
model (a) or remotely in vivo
model (b)
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standardized difference in means (SMD; the mean of the con-
trol group minus the mean of the RIPC group, divided by the
pooled SD of the two groups) [4].
The two-tailed significance level was set at P < 0.05.
STATA software version 13.1 (Stata Corp, College Station,
TX, USA) and GraphPad Prism version 6.00 (GraphPad
Software, La Jolla California, USA) were used to perform
the analyses and produce the graphs.
Results
Local Ischaemic Preconditioning
The analysis contained five independent experiments, in-
cluding data for 27 control mice and 29 animals that
underwent IPC. Overall, IPC reduced infarct size in the
area at risk by a mean difference of 24.1% (95% CI 19.5
to 28.6%) when compared to untreated controls
(P < 0.001) (Fig. 2). Notably, IPC treatment effect was
consistent across all experiment sets, and some between-
experiment variation was observed (the minim effect size
was 12.3%, whilst the maximum effect size was 38.1%).
Importantly, between-experiment variance was taken into
account to estimate the overall treatment effect.
Remote Ischaemic Preconditioning
The analysis contained three independent experiments, in-
cluding data for 16 control mice and 19 animals that
underwent RIPC. Overall, RIPC diminished infarct size in
the area at risk by a mean difference of 20.8% (95% CI 14.7
to 26.9%) when compared to untreated controls (P < 0.001).
Notably, RIPC treatment effect was consistent across all ex-
periment sets, although some heterogeneity (between-
experiment variation) was observed: the treatment effect
ranged between 13.4 and 27.6% (Fig. 3).
Sensitivity Analysis
When re-running our analysis using the standardized
mean difference (SMD), all results were similar to those
found using the weighted absolute difference in means.
We found a highly significant (P < 0.001) overall effect
of IPC (SMD of 6.3; 95% CI 4.07–8.43). Similarly, we
found a highly significant (P < 0.001) summary SMD of
 −12.3 (−20.5, −4.1)
 −16.9 (−25.0, −8.7)
 −38.1 (−53.0 −23.3)
 −26.4 (−34.7, −18.0)
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Fig. 2 Effect of local IPC on
myocardial infarct size in the
ex vivo mouse model of IRI.
Panel a displays raw data for each
independent experiment. Panel b
depicts a forest plot where left
side of the x axis favours IPC and
the right side favours control. An
overall beneficial effect of IPC
was observed. Crude mean
difference are reported for each
independent experiment, whilst
the combined mean difference
estimated through a random-
effects model is reported for the
overall estimate. The random-
effect model provides an accurate
estimation by weighting each ex-
periment according to their preci-
sion and allowing for some ex-
pected random heterogeneity
(between-experiment variation)
inherent to all biological
processes
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5.49 (95% CI 3.91, 7.08) for RIPC. Of note, the mag-
nitude and direction of treatment effect for both IPC
and RIPC, as well as the level of significance did not
change substantially.
Discussion
Our present data indicate that local IPC reduces myocardial
infarct size by a mean difference of 24.1% (95% CI 19.5 to
28.6%) and RIPC diminishes myocardial damage by a mean
difference of 20.8% (95% CI 14.7 to 26.9%). Notably, the
direction of the results was consistent across sets of experi-
ments, and the overall estimate remained consistent in a sen-
sitivity analysis using standardized mean differences. In this
study, we pooled the results from eight separate experiments
testing for two interventions carried out in our Institute over
the last 3 years in order to obtain precise estimates of efficacy.
Efforts to avoid bias and random error are as important
when reviewing the results of experimental models as when
reviewing the results of human studies, given that this evi-
dence would be used to determine which interventions are
taken forward in clinical trials. This would apply for all
cardioprotective interventions which can potentially be trans-
lated to the clinical setting and would imply that further efforts
are needed to accurately estimate treatment effects discounting
both the effect of chance and biological variability, before
concluding that these results can be translated to the clinical
setting thought a randomized trial. Notably, previous meta-
analysis in different fields of preclinical research shows that
publication bias and methodological flaws are often responsi-
ble for systematic effect size overestimation and thereby in-
correct conclusion about efficacy [1]. Thus, it is needed to
estimate treatment effect using standardized protocols in rela-
tively homogenous experimental conditions. Using data al-
ready collected is in accordance with the principles of the
3Rs (reduction and replacement of animals and refinement
of procedures), which represent the cornerstone of sensible
and streamlined animal research [12].
Since the clinical feasibility of local and remote ischaemic
preconditioning in IRI is mainly limited to elective interven-
tion, such as interventional or surgical coronary revasculari-
zation, we believe that our results have implication in other
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Fig. 3 Effect of RIPC on
myocardial infarct size in the
in vivomousemodel of IRI. Panel
a displays raw data for each
independent experiment. Panel b
depicts a forest plot where left
side of the x axis favours IPC and
the right side favours control.
RIPC showed an overall
beneficial effect. Crude mean
difference are reported for each
independent experiment, whilst
the combined mean difference
estimated through a random-
effects model is reported for the
overall estimate
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as the standard for other cardioprotective interventions to de-
termine by howmuchmyocardial IS can be reduced following
an IRI insult. Our observations may contribute to more suc-
cessful development of new therapies aimed to reduce myo-
cardial IRI, as cardioprotective therapies providing a limited
treatment effect in comparison with expected IS reduction
provided by the gold-standard (IPC or RIPC) should be re-
assessed before moving the research towards the clinical set-
ting. Moreover, taking into account that our estimate effect
size is the result of pooling more than 90 animals in a single
dataset, we believe that these results are of potential use when
establishing positive controls within a set of experiments. IPC
has become the paradigm to study molecular signalling in
cardioprotection [8, 10, 13] and researchers can use our values
to compare whether their IPCmodels sufficiently reduce myo-
cardial infarct size or whether they need to change the protocol
to obtain a more suitable model. Small rodent animals of AMI
have been extensively used over the last decades to elucidate
the pathologic responses to IRI, and their use has provided
substantial insights of the molecular signalling underlying
most of the cardioprotective interventions, thus unveiling po-
tential drug targets.
The magnitude of infarct size reduction using either IPC or
RIPC estimated at individual animal-level in our study is sim-
ilar to those reported in previous meta-analyses using aggre-
gated data in highly heterogeneous backgrounds [4, 6, 14].
Most of these studies lack the consistency of using a single
standardized protocol, as most of them have pooled data from
both local and remote conditioning and have pooled together
results from different protocols (i.e. number and duration of
cycles), and some of these results have been reported for dif-
ferent organs (i.e. heart, kidney). Notably, our results define
with precision the magnitude of the effect of the protection
afforded by IPC in an adequately-sized subset of experiments
in two well-defined and recognized models using standard
protocols consistently in the same organ.
Given that all the experiments were performed in the
same laboratory, we observed less heterogeneity in our
statistical analysis in comparison with previous meta-
analysis of pre-clinical studies. This is a double-edged
sword, as in one hand we obtained more precise estimates,
but on the other hand, this should be understood as a lim-
itation to generalize our results. Moreover, caution should
be taken when extrapolating our findings to other settings,
given that we used young animals with no comorbidities.
The failure to translate cardioprotective therapies into the
clinical setting has been attributed to a disconnection be-
tween animal models and the clinical setting [15]. It is
important to appreciate that our study was not designed
to address this disconnection. However, it would be impor-
tant to undertake similar studies to that of the above, using
comorbid animals to better understand their influence on
myocardial infarction.
In conclusion, using a relatively large animal data set, we
found that local IPC reduces myocardial infarct size by 24.1%
and RIPC by 20.8% in the ex vivo and in vivo mouse models
of IRI, respectively. These values may become reference
values for other researchers to either establish their positive
controls or to determine by how much myocardial infarct size
can be reduced by novel cardioprotective interventions fol-
lowing an IRI insult.
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